Clinical Trial Update: A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II trial investigating Pexa-Vec oncolytic virus in combination with immune checkpoint inhibitor for refractory colorectal cancer has completed, with res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Colorectal Adenocarcinoma
• Colorectal Cancer
• Colorectal Carcinoma
• Colorectal Neoplasms

Drugs mentioned

• Pexa-Vec (pexastimogene devacirep)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Colorectal Cancer, Colorectal Carcinoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-10-26